Results 121 to 130 of about 27,373 (254)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?

Research and Practice in Thrombosis and Haemostasis
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis,
Yachar Dawudi, Samuel Benarroch, Hélène Helfer, David M. Smadja, Isabelle Mahé   +4 more
doaj   +1 more source

Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis

Journal of Internal Medicine, Volume 299, Issue 6, Page 741-753, June 2026.
Abstract Objectives To investigate, in early rheumatoid arthritis, whether bridging with glucocorticoids (GCs) is associated with an increased risk of flare following GC tapering and withdrawal. Methods A total of 810 NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD‐STAR) patients were included in this post hoc analysis: all received ...
Kristina Lend, Jos W. R. Twisk, Frieda A. Koopman, Anna Rudin, Merete Lund Hetland, Till Uhlig, Dan C. Nordström, Michael T. Nurmohamed, Bjorn Gudbjornsson, Kim Hørslev‐Petersen, Marte Schrumpf Heiberg, Tuulikki Sokka‐Isler, Gerdur Grondal, Espen A. Haavardsholm, Mikkel Østergaard, Jon Lampa, Ronald van Vollenhoven   +16 more
wiley   +1 more source

The “Tianyu” Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase‐1/GSDMD‐Mediated Pyroptosis Pathway

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Proposed signaling pathway by which TY modulates NLRP3/Caspase‐1/GSDMD‐mediated pyroptosis. ABSTRACT This research focuses on exploring the modulation of pyroptosis and its underlying mechanisms via the “Tianyu” formulation (TY), a traditional Chinese medicine, in human rheumatoid arthritis fibroblast‐like synovial cells (RA‐HFLS) and a collagen ...
Yueya Zhu, Xinying Cai, Qiuhan Zheng, Chunqiu Fang, Zhi Pan, Yinghang Wang   +5 more
wiley   +1 more source

The role of disease-modifying antirheumatic drugs in the implementation of the «treat-to-target» strategy for rheumatoid arthritis

Каразінський імунологічний журнал
Background. Rheumatoid arthritis is a chronic systemic autoimmune disease that remains one of the leading causes of disability worldwide. Effective management of this condition requires a modern approach focused on the early achievement of therapeutic ...
F.V. Hladkykh
doaj   +1 more source

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab. [PDF]

, 2019
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX ...
DeHoratius, Raphael J., Ellis, Lorie A., Kafka, Shelly, Kubacki, Maureen, Malangone-Monaco, Elisabetta, Stetsovsky, Diana, Varker, Helen   +6 more
core   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

Arthritis Care &Research, Volume 78, Issue 5, Page 662-669, May 2026.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung, John P. Shelley, Gul Karakoc, John Still, Xiaodi Ruan, Jonathan Mosley, C. Michael Stein, Vivian K. Kawai   +7 more
wiley   +1 more source

The use of topical diclofenac in the pain management of osteoarthritis of the knee [PDF]

, 2006
Osteoarthritis (OA) is a common complaint that affects millions of people worldwide. As there is no cure for OA, drug treatment is the main form of management.
Banning, M
core  

Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.

JAMA Netw Open, 2022
Desai RJ, Varma VR, Gerhard T, Segal J, Mahesri M, Chin K, Horton DB, Kim SC, Schneeweiss S, Thambisetty M.   +9 more
europepmc   +1 more source

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo, Alan Y. Hsu, De‐Yi Liu, Bing‐Qi Wu, James Cheng‐Chung Wei, Ning‐Yi Hsia, Yi‐Ching Shao, Chun‐Ting Lai, Chun‐Chi Chiang, Chun‐Ju Lin, Huan‐Sheng Chen, Yu‐Hsun Wang, Hsin Tseng, Ho‐Che Hsu, Yi‐Yu Tsai   +14 more
wiley   +1 more source

Periodontal Indices in Patients with Rheumatoid Arthritis Undergoing Immunosuppressive Therapy [PDF]

مجله دانشگاه علوم پزشکی گرگان
Background and Objective: Periodontitis and rheumatoid arthritis are two chronic inflammatory diseases that are interrelated. Given the similarities between these conditions, the medications used by patients with rheumatoid arthritis (RA) may affect ...
Ilnaz Frahoudi, Afsaneh Enteshari-Moghaddam, Zakiyeh Movahedzadeh   +2 more
doaj